Nurix Therapeutics Inc (NASDAQ: NRIX) is -39.60% lower on its value in year-to-date trading and has touched a low of $10.37 and a high of $29.56 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The NRIX stock was last observed hovering at around $10.47 in the last trading session, with the day’s gains setting it 0.91%.
Currently trading at $11.38, the stock is -13.18% and -28.36% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.23 million and changing 8.69% at the moment leaves the stock -44.99% off its SMA200. NRIX registered -21.95% loss for a year compared to 6-month loss of -49.35%. The firm has a 50-day simple moving average (SMA 50) of $15.8855 and a 200-day simple moving average (SMA200) of $20.68615.
The stock witnessed a -20.20% gain in the last 1 month and extending the period to 3 months gives it a -38.95%, and is -10.60% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.81% over the week and 6.46% over the month.
Nurix Therapeutics Inc (NRIX) has around 286 employees, a market worth around $863.60M and $54.55M in sales. Profit margin for the company is -354.85%. Distance from 52-week low is 9.74% and -61.50% from its 52-week high. The company has generated returns on investments over the last 12 months (-35.37%).
with sales reaching $12.11M over the same period.The EPS is expected to shrink by -11.79% this year, but quarterly earnings will post 0.74% year-over-year. Quarterly sales are estimated to shrink -26.97% in year-over-year returns.
249.0 institutions hold shares in Nurix Therapeutics Inc (NRIX), with institutional investors hold 111.39% of the company’s shares. The shares outstanding are 75.87M, and float is at 74.38M with Short Float at 16.36%. Institutions hold 109.89% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 6.82 million shares valued at $142.33 million. The investor’s holdings represent 10.9334 of the NRIX Shares outstanding. As of 2024-06-30, the second largest holder is REDMILE GROUP, LLC with 4.42 million shares valued at $92.32 million to account for 7.0917 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 3.63 million shares representing 6.6025 and valued at over $75.65 million, while DEEP TRACK CAPITAL, LP holds 6.3989 of the shares totaling 3.99 million with a market value of $83.3 million.
Nurix Therapeutics Inc (NRIX) Insider Activity
The most recent transaction is an insider sale by van Houte Hans, the company’s Chief Financial Officer. SEC filings show that van Houte Hans sold 5,825 shares of the company’s common stock on Mar 03 ’25 at a price of $14.49 per share for a total of $84388.0. Following the sale, the insider now owns 33724.0 shares.
Still, SEC filings show that on Jan 31 ’25, Ring Christine (Chief Legal Officer) disposed off 5,760 shares at an average price of $19.95 for $0.11 million. The insider now directly holds 32,538 shares of Nurix Therapeutics Inc (NRIX).
